The forecast for the sold production of hormones, prostaglandins, thromboxanes, and leukotrienes in France from 2024 to 2028 shows a slight downward trend, with values decreasing from 159.0 million euros in 2024 to 158.31 million euros by 2028. Estimated from actual data, the production was approximately 159.2 million euros in 2023. Year-on-year variations indicate a consistent but marginal decline, with the compound annual growth rate (CAGR) over the five-year forecasted period highlighting a slight contraction.

Future trends to watch for include potential shifts in global demand, advancements in synthetic biology that could influence production methods, and regulatory changes in healthcare policies that might impact both production capability and market access in France.

The forecast predicts a gradual, steady decline in sold production value.
Consideration of technological advancements and regulatory impacts is crucial.
Monitoring global demand changes is essential for anticipating future market shifts.